FLORA GROWTH CORP. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.201 USD | -2.39% |
|
-6.20% | -11.07% |
| May. 16 | Roth MKM Adjusts Price Target on Flora Growth to $6 From $7, Maintains Buy Rating | MT |
| May. 15 | Transcript : Flora Growth Corp., Q1 2024 Earnings Call, May 15, 2024 |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -11.07% | 15.72M | - | ||
| -.--% | 339M | - | - | |
| +44.44% | 299M | - | ||
| +23.71% | 279M | - | ||
| +56.40% | 206M | C | ||
| +161.28% | 154M | - | - | |
| +44.28% | 132M | - | ||
| -42.86% | 122M | - | - | |
| -42.86% | 119M | C | ||
| +7.69% | 118M | - | - |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- FLGC Stock
- Ratings Flora Growth Corp.